Surgical Pembro +/- Olaparib w TMZ for rGBM

PHASE2RecruitingINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

October 21, 2022

Primary Completion Date

February 1, 2026

Study Completion Date

November 1, 2026

Conditions
GlioblastomaRecurrent Glioblastoma
Interventions
DRUG

Pembrolizumab

Intravenous infusion

DRUG

Olaparib

Pill taken by mouth

DRUG

Temozolomide

Pill taken by mouth

Trial Locations (4)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

02114

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Beth Israel Deaconess Medical Center, Boston

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

L. Nicolas Gonzalez Castro, MD, PhD

OTHER